# Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

> **NCT01349959** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 58 (actual)

## Conditions studied

- Male Breast Carcinoma
- Recurrent Breast Carcinoma
- Stage IIIC Breast Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7
- Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Entinostat
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01349959
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08-15
- **Primary completion:** 2014-03-27
- **Final completion:** 2023-11-07
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01349959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01349959, "Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01349959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*